title: Lessons drawn from recent HIV vaccine efficacy trials.
abstract: A safe and effective HIV vaccine is needed to curtail the US and global epidemics. However, the search for one has been elusive despite more than 25 years of focused research. Results from the RV144 Thai efficacy trial have renewed hope that a vaccine may protect against HIV acquisition. We can draw several scientific and operational lessons from RV144 and other recent tests-of-concept efficacy trials. Here we describe how trial results, some unexpected, highlight the fundamental role these clinical studies play in HIV vaccine discovery. These trials also teach us that transparency in data analysis and results dissemination can yield substantial rewards and that efforts to engage communities, particularly those most heavily affected by the epidemic, are needed to augment research literacy and trial recruitment. Future efficacy trial designs may incorporate novel, partially effective prevention strategies. Although greater in size and complexity, these trials may offer unique opportunities to explore synergies with vaccines under study.
authors.affiliation: HIV Research Section, San Francisco Department of Public Health, San Francisco, CA 94102, USA. jonathan.fuchs@sfdph.org
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Fuchs
authors.forename: Magda E
authors.initials: ME
authors.lastname: Sobieszczyk
authors.forename: Scott M
authors.initials: SM
authors.lastname: Hammer
authors.forename: Susan P
authors.initials: SP
authors.lastname: Buchbinder
mesh_terms: D016915:AIDS Vaccines / Q000592:standards*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D012107:Research Design; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines